Key Takeaways

• Moorfields Private has introduced specialist eye assessments for patients taking GLP-1 medications, including individuals using the drugs for weight management who may not receive routine diabetic eye screening
• The service provides ophthalmologist-led assessment, retinal imaging and individualized guidance on whether additional ocular monitoring is appropriate
• The launch follows February 2026 MHRA guidance identifying NAION as a very rare adverse effect associated with semaglutide and advising urgent ophthalmic evaluation for sudden vision loss

Moorfields Private has launched an eye health assessment service for patients taking GLP-1 medications for weight management, offering specialist retinal screening and ophthalmic consultation to individuals who may not be covered by routine NHS diabetic eye screening programs.

The service comes amid increasing attention to the potential ocular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related medications, including semaglutide and tirzepatide. These medications are used for indications including type 2 diabetes and weight management.

Although current evidence does not indicate that every patient taking a GLP-1 medication requires additional ophthalmic monitoring, Moorfields said patients with preexisting eye disease, visual symptoms or concerns about their ocular health may benefit from specialist assessment.

The new service includes comprehensive eye health assessment by a specialist ophthalmologist, advanced retinal imaging and screening, individualized advice about monitoring while taking GLP-1 medications, and access to additional investigation or treatment when indicated.

Moorfields Private already offers ophthalmic screening incorporating diagnostic technologies such as optical coherence tomography and ultrawide-field retinal imaging, with results reviewed by consultant ophthalmologists.

“GLP-1 medications have delivered significant health benefits for many patients, particularly those living with obesity and type 2 diabetes,” Sharon Heng, consultant ophthalmic surgeon at Moorfields Private and Moorfields Eye Hospital NHS Foundation Trust, said in a statement. “However, as their use becomes more widespread, patients are understandably asking questions about potential effects on eye health.”

Heng added that evidence concerning ocular effects continues to evolve and that most patients taking the medications do not need to be concerned.

“However, patients taking GLP-1 medications may value the reassurance of a specialist eye assessment, particularly if they already have an eye condition or have noticed changes in their vision,” she said.

Regulatory attention on semaglutide and NAION

The service launch follows updated guidance issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026 regarding a very rare risk of nonarteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide.

The MHRA updated product information for semaglutide-containing medicines after NAION was very rarely reported in patients receiving semaglutide for type 2 diabetes, weight management and cardiovascular risk reduction. The condition results from reduced blood flow to the anterior optic nerve and typically causes sudden, painless vision loss in 1 eye.

The regulator advises that patients who experience sudden loss of vision, including partial vision loss, while receiving semaglutide should be urgently referred for ophthalmologic assessment. If NAION is confirmed, semaglutide treatment should be discontinued, according to the MHRA guidance.

Research also continues into possible associations between GLP-1 medications and other ocular conditions, including diabetic retinopathy and age-related macular degeneration.

Moorfields emphasized that the overall health benefits of GLP-1 medications continue to outweigh potential ocular risks for most patients. Patients who develop sudden vision loss or rapidly worsening vision should seek urgent medical care. Moorfields also advises urgent assessment for symptoms including a sudden increase in floaters, flashes of light or a dark, curtain-like change in vision.

The financial surplus generated by Moorfields Private is reinvested into Moorfields Eye Hospital to support NHS services, according to the organization.